



Media Statement

March 5, 2021

Johnson & Johnson Reaffirms Commitment to Deliver its Janssen COVID-19 Vaccine Candidate to European Union Vaccine Steering Committee and Member States

Janssen, the Pharmaceutical Companies of Johnson & Johnson, is pleased to have had an opportunity to meet with members of the European Union Vaccine Steering Committee and Member States today, 5 March 2021, to reaffirm our commitment to deliver 200 million doses of its single dose COVID-19 vaccine candidate to the EU in 2021 starting in the second quarter. Our vaccine candidate has been submitted to the European Medicines Agency (EMA) for conditional Marketing Authorization Application (cMAA) and is subject to approval.

Since January 2020, we have been working directly with governments, health authorities and other companies to help end this pandemic. To achieve our ambitious goals to deliver our COVID-19 vaccine candidate, we have focused on building a global supply network in parallel. We continue to start-up and activate new manufacturing sites as quickly as possible, such as the collaborations with Catalent, Reig Jofre and Sanofi Pasteur.

As part of our commitment to transparency, we intend to provide another update to the European Commission and Member States on our supply during our next meeting mid-March when the European Union Vaccine Steering Committee meets again.

###